![](https://scsb.mit.edu/wp-content/uploads/2018/01/20180126-Rapamycin844-570x350.jpg)
Source: [Spectrum, Hannah Furfaro | January 26, 2018] The drug rapamycin, which is in clinical trials for tuberous sclerosis (TSC), exacerbates features of fragile X syndrome, another condition related to autism, a new study suggests1. Rapamycin increases anxiety, shortens sleep and worsens social skills in a mouse model of fragile X syndrome, the […]